184 related articles for article (PubMed ID: 30903752)
1. The association between activated protein C ratio and Factor V Leiden are gender-dependent.
Hansen RS; Nybo M
Clin Chem Lab Med; 2019 Jul; 57(8):1229-1234. PubMed ID: 30903752
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
Gessoni G; Valverde S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
[TBL] [Abstract][Full Text] [Related]
3. A 9-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations.
Favaloro EJ; Orsag I; Bukuya M; McDonald D
Pathology; 2002 Aug; 34(4):348-55. PubMed ID: 12190294
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity and specificity of the APC resistance assay in detection of individuals with factor V Leiden.
Zehnder JL; Benson RC
Am J Clin Pathol; 1996 Jul; 106(1):107-11. PubMed ID: 8701918
[TBL] [Abstract][Full Text] [Related]
5. The response to activated protein C after cardiopulmonary bypass: impact of factor V leiden.
Donahue BS
Anesth Analg; 2004 Dec; 99(6):1598-1603. PubMed ID: 15562039
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Testing Approaches for Activated Protein C Resistance and Factor V Leiden: A Comparison of Institutional and National Provider Practices.
Perez Botero J; Majerus JA; Strege AK; Johnson RD; Chen D; Pruthi RK
Am J Clin Pathol; 2017 Jun; 147(6):604-610. PubMed ID: 28472350
[TBL] [Abstract][Full Text] [Related]
7. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays.
Favaloro EJ; Mirochnik O; McDonald D
Br J Biomed Sci; 1999; 56(1):23-33. PubMed ID: 10492912
[TBL] [Abstract][Full Text] [Related]
8. The procoagulant effects of factor V Leiden may be balanced against decreased levels of factor V and do not reflect in vivo thrombin formation in newborns.
Hyytiäinen S; Wartiovaara-Kautto U; Ulander VM; Kaaja R; Heikinheimo M; Petäjä J
Thromb Haemost; 2006 Mar; 95(3):434-40. PubMed ID: 16525570
[TBL] [Abstract][Full Text] [Related]
9. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis.
de Visser MC; Guasch JF; Kamphuisen PW; Vos HL; Rosendaal FR; Bertina RM
Thromb Haemost; 2000 Apr; 83(4):577-82. PubMed ID: 10780320
[TBL] [Abstract][Full Text] [Related]
10. Resistance to activated protein C, factor V leiden and the prothrombin G20210A variant in patients with colorectal cancer.
Paspatis GA; Sfyridaki A; Papanikolaou N; Triantafyllou K; Livadiotaki A; Kapsoritakis A; Lydataki N
Pathophysiol Haemost Thromb; 2002; 32(1):2-7. PubMed ID: 12214157
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of activated protein C resistance and factor V Leiden mutation in an Arab population and patients with venous thrombosis in Kuwait.
Jadaon MM; Dashti AA; Lewis HL
Diagn Mol Pathol; 2010 Sep; 19(3):180-3. PubMed ID: 20736749
[TBL] [Abstract][Full Text] [Related]
12. [Activated protein C resistance, Leiden mutation, anticoagulant proteins and fibrinogen levels in patients with deep venous thrombosis].
Jastrzebska M; Bałszan-Kowalska I; Ciechanowicz A; Bińczak-Kuleta A; Falkowski A; Chełstowski K
Pol Arch Med Wewn; 2003 Jun; 109(6):579-88. PubMed ID: 14567090
[TBL] [Abstract][Full Text] [Related]
13. Factor V Leiden mutation and other thrombophilia markers in childhood ischemic stroke.
Duran R; Biner B; Demir M; Celtik C; Karasalihoğlu S
Clin Appl Thromb Hemost; 2005 Jan; 11(1):83-8. PubMed ID: 15678277
[TBL] [Abstract][Full Text] [Related]
14. Genetic Testing for Thrombophilia-Related Genes: Observations of Testing Patterns for Factor V Leiden (G1691A) and Prothrombin Gene "Mutation" (G20210A).
Favaloro EJ
Semin Thromb Hemost; 2019 Oct; 45(7):730-742. PubMed ID: 31398733
[TBL] [Abstract][Full Text] [Related]
15. Factor V Leiden-independent activated protein C resistance: Communication from the plasma coagulation inhibitors subcommittee of the International Society on Thrombosis and Haemostasis Scientific and Standardisation Committee.
Moore GW; Castoldi E; Teruya J; Morishita E; Adcock DM
J Thromb Haemost; 2023 Jan; 21(1):164-174. PubMed ID: 36695379
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit APC-R Factor V Leiden) at two centers in Europe and the USA.
Schöni R; Quehenberger P; Wu JR; Wilmer M
Thromb Res; 2007; 119(1):17-26. PubMed ID: 16934314
[TBL] [Abstract][Full Text] [Related]
17. Plasma homocysteine concentration is not associated with activated protein C resistance in patients investigated for hypercoagulability.
Zarychanski R; Houston DS
Thromb Haemost; 2004 Jun; 91(6):1115-22. PubMed ID: 15175797
[TBL] [Abstract][Full Text] [Related]
18. [Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population].
Ehrenforth S; Klinke S; von Depka Prondzinski M; Kreuz W; Ganser A; Scharrer I
Dtsch Med Wochenschr; 1999 Jun; 124(25-26):783-7. PubMed ID: 10414227
[TBL] [Abstract][Full Text] [Related]
19. Activated protein C resistance -- in the absence of factor V Leiden -- and pregnancy.
Lindqvist PG; Svensson P; Dahlbäck B
J Thromb Haemost; 2006 Feb; 4(2):361-6. PubMed ID: 16420566
[TBL] [Abstract][Full Text] [Related]
20. Endogenous thrombin potential for predicting risk of venous thromboembolism in carriers of factor V Leiden.
Lincz LF; Lonergan A; Scorgie FE; Rowlings P; Gibson R; Lawrie A; Seldon M
Pathophysiol Haemost Thromb; 2006; 35(6):435-9. PubMed ID: 17565236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
